Summary of patients who developed a secondary autoimmune disorder
| . | Primary disease . | Regimen . | CD34-selected PBSCs . | Current status of primary disease . | Secondary autoimmune disorder (time of onset) . | Treatment of secondary disorder . | Outcome of secondary disorder . |
|---|---|---|---|---|---|---|---|
| 1 | SLE | Cy/ATG | Yes | Remission | FVIII inhibitor (30 mo) | FVIIa, RTX, pred | Resolved |
| 2 | SLE | Cy/ATG | Yes | Persistent | FVIII inhibitor (9 mo) | FVIIa, MP, RTX, Cy, MMF | Resolved |
| 3 | MS | Cy/alemtuzumab | No | Remission | ITP (8 mo) | IVIG, MP, RTX, pred | Resolved |
| 4 | SSc | Cy/alemtuzumab | No | Remission | AIHA (5 mo) | IVIG, MP, MMF, pred, RTX, Cy | Controlled |
| 5 | SLE | Cy/alemtuzumab | No | Remission | Autoimmune neutropenia/AIHA (2 mo) | IVIG, MP, RTX, Cy, MMF, pred, tacrolimus, splenectomy | Controlled |
| 6 | MS | Cy/alemtuzumab | No | Remission | ITP (14 mo) | IVIG, MP, RTX, MMF | Resolved |
| . | Primary disease . | Regimen . | CD34-selected PBSCs . | Current status of primary disease . | Secondary autoimmune disorder (time of onset) . | Treatment of secondary disorder . | Outcome of secondary disorder . |
|---|---|---|---|---|---|---|---|
| 1 | SLE | Cy/ATG | Yes | Remission | FVIII inhibitor (30 mo) | FVIIa, RTX, pred | Resolved |
| 2 | SLE | Cy/ATG | Yes | Persistent | FVIII inhibitor (9 mo) | FVIIa, MP, RTX, Cy, MMF | Resolved |
| 3 | MS | Cy/alemtuzumab | No | Remission | ITP (8 mo) | IVIG, MP, RTX, pred | Resolved |
| 4 | SSc | Cy/alemtuzumab | No | Remission | AIHA (5 mo) | IVIG, MP, MMF, pred, RTX, Cy | Controlled |
| 5 | SLE | Cy/alemtuzumab | No | Remission | Autoimmune neutropenia/AIHA (2 mo) | IVIG, MP, RTX, Cy, MMF, pred, tacrolimus, splenectomy | Controlled |
| 6 | MS | Cy/alemtuzumab | No | Remission | ITP (14 mo) | IVIG, MP, RTX, MMF | Resolved |
PBSCs indicates peripheral blood stem cells; HSCT, hematopoietic stem cell transplantation; SLE, systemic lupus erythematosus; MS, multiple sclerosis; SSc, systemic sclerosis; Cy, cyclophosphamide; ATG, antithymocyte globulin; FVIII, factor VIII; ITP, immune thrombocytopenia purpura; AIHA, autoimmune hemolytic anemia; FVIIa, recombinant activated factor VII; RTX, rituximab; pred, prednisone; MP, methylprednisolone; MMF, mycophenolate mofetil; and IVIG, intravenous immunoglobulin.